Updated Feb. 16, 2017 at 6:40 a.m.

Duke oncology startup led by former Trimeris CEO raises $4M

Published: 2017-02-16 06:40:00
Updated: 2017-02-16 06:40:11

Cancer research  Cancer research

Istari Oncology, a North Carolina-based company, raised nearly $4 million in a private stock offering, according to a Securities and Exchange Commission filing.

Istari Oncolgoy filed the Form D on Feb. 13. It did not disclose what it tended to do with the proceeds.

The company began in 2014 as a Duke University start-up and works to cure recurrent glioblastoma [a form of brain cancer]. Executive officers and directors Dani Bolognesi, Henry Friedman and Darell Bigner lead the company.

Bolognesi is the former chief executive officer of Trimeris, which developed AIDS drugs. He is also the director of the Center for AIDS Research at Duke University.

Friedman is a professor of pediatric oncology at Duke while Bigner is a cancer research professor.

Companies relying on a Reg D exemption do not have to register their offering of securities with the SEC, but they must file what’s known as a Form D electronically after they first sell their securities.

Note: This story is from the North Carolina Business News Wire, a service of UNC-Chapel Hill’s School of Media and Journalism

WRAL TechWire any time: Twitter, Facebook

Copyright 2017 The University of North Carolina at Chapel Hill. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Latest for Insiders